



A review on trabectedin

Syed Aamer Nawaz

Doctor of Pharmacy (PharmD), Samskruti College of Pharmacy, Jawaharlal Nehru Technological University-Hyderabad (JNTUH), Hyderabad, Telangana, India

DOI: <https://doi.org/10.33545/26647184.2019.v1.i1a.2>

Abstract

Trabectedin is a drug which belongs to class Anti-Neoplastic agents and is available in a powdered dosage form for reconstitution. It is derived from *Ecteinascidia turbinata* which is a Caribbean marine tunicate. Trabectedin is also called as Ecteinascidin and is generally used for the treatment of Soft Tissue Sarcoma (STS) and in Ovarian Cancer. Unlike other neoplastic agents, Trabectedin binds to the minor groove of DNA which results in the structural changes of DNA that may cause cell death. Trabectedin also interferes with the transcription, repair pathway and also blocks G2 and M phase of cell cycle. Due to these events cell proliferation ceases. In this manner trabectedin shows its anti-tumor effects.

Keywords: trabectedin, anti-neoplastic agent, soft tissue sarcoma, ovarian cancer

Introduction

Trabectedin is a marine alkaloid that is isolated from the tunicate *Ecteinascidia turbinata*.

This is an anti-neoplastic drug which have been found efficient in the treatment of soft tissue cancers.

When it comes to the availability of the drug it's a bit of scarcity as it requires 1 ton of *Ecteinascidia turbinata* to produce 1 gram of Trabectedin which makes it a way more expensive.

To overcome this scientists have developed a semi synthetic method for the production of Trabectedin.

Amino acid Tyrosine is involved in the synthesis of trabectedin which forms an intermediate product which is used as a starting material for the production of two halves of trabectedin molecule which are binded together in the later reactions.

There are 2 to 3 Tetrahydroisoquinoline sub-units along with active carbinolamine functional group which are responsible for showing potent anti-proliferative activity.

The semi synthetic method of production of trabectedin involves readily available cyanosafrafin B.




Fig 1

The above figure shows the steps involved in the production of trabectedin from cyanosafraicin B.

Hence by synthesizing of Trabectedin synthetically the need of sea squirts for isolation of trabectedin have been decreased.

Mechanism

Although the exact mechanism is unknown till now, it have been noticed that trabectedin binds to the minor groove of DNA unlike other neoplastic agents which bind to major groove of DNA.

After binding to the minor groove of DNA it bends the DNA towards the major groove and interferes with the Transcription Coupled Nucleotide Excision Repair pathway (TC-NER) which leads to structural changes in DNA that may cause its damage which alters its normal functions such as repair and transcription that ultimately leads to cessation of cell proliferation, cell differentiation and causes Apoptosis or Cell Death. It also blocks the G2 and M phase of cell cycle (selective inhibitor of transcription).




Fig 2

Pharmacological Properties

Distribution

Trabectedin is mostly administered intravenously and is extensively distributed in tissues.

Volume of distribution is greater than 5,000 L.

Protein bound- ~97%

Metabolism

Trabectedin is metabolized in liver by Cytochrome P450 (CYP) pathway.

Excretion

Extensively metabolized, with negligible unchanged drug in urine and feces.

Half-life of trabectedin is found to be 175hr.

Clearance – 31.5 L/hr.

Studies suggest that if Trabectedin is given in combination with other anti-neoplastic drugs it shows additive or synergistic effects.

Tolerability

Toxicity profile of trabectedin can be managed easily as it shows mostly grade I and grade II adverse effects and are reversible.

Grade III and grade IV adverse effects are severe. For example Neutropenia, in this neutrophil count is abnormally decreased.

The most frequent adverse effect was elevation of serum ALT or AST levels due to frequent treatment.

Trabectedin triggers NK-mediated Cytotoxicity in Multiple Myeloma

Multiple Myeloma is the cancer of plasma cells in which genomic instability is seen.

Alteration in DNA repair pathways contributes to the genomic instability.

Changes in Cytokine production and release was noticed.

Studies suggest that Trabectedin induces the activation of NK cells, DNA Damaging Response (DDR) and cellular stress with cell cycle arrest.

It was also found that trabectedin triggers apoptosis in multiple myeloma.

Drug-induced cell stress in multiple myeloma cells leads to upregulation of NK activating receptor ligands which results in increased NK cell activation and degranulation.

And hence it is found that trabectedin triggers NK-mediated cytotoxicity in multiple myeloma.

Trabectedin Decreases Skeletal Prostate Cancer Tumor Size

It decreases the tumor size and also shows effect on Macrophages and efferocytosis. Efferocytosis is a process in which the dead cells are removed by the phagocytic cells. Macrophages play a prominent role in regulating tumor progression as it can either reduce tumor growth or promote tumor growth.

Bone Marrow is rich with monocytic cells so it serves as the site for prostate cancer. Trabectedin is identified to have ability to induce apoptosis in macrophages and monocytes. Studies suggest that macrophage effects are important for trabectedin to exert its therapeutic benefits.

Studies suggests Macrophage efferocytosis as a critical cell function which increases prostate cancer cell growth. So far no curative treatment have been found for prostate cancer bone metastasis and most of the patients who die because of prostate cancer have involvement of bone.

Trabectedin is found to be able to target M2-like macrophages and their efferocytosis by which it shows its potential in treatment of prostate cancer skeletal metastatic tumor growth.

Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma

Cutaneous Melanoma is a serious skin cancer.

Apart from targeting cancer cells, Trabectedin also shows effect on tumor microenvironment, its vasculature and immune response.

Trabectedin shows significant reduction in the tumor blood vessel density and associated macrophages thereby inhibiting the subcutaneous growth of murine melanoma.

According to some studies, trabectedin also shows significant Anti-metastatic activity thereby inhibiting the formation of lung colonies.

Trabectedin also inhibits melanoma cell invasiveness.

Hepatoprotective effect of N-acetyl cysteine in Trabectedin induced Liver Toxicity

Trabectedin is one of the most efficient anti-neoplastic agent used in the treatment of Soft Tissue Sarcomas but hepatotoxic effect is seen most frequently which represents a dose limiting factor.

N-acetyl cysteine is found to have antioxidant properties which shows hepatoprotective effect.

This makes us consider use of N-acetyl cysteine to overcome the major side effect that is liver toxicity which is induced by trabectedin.

Studies suggests that N-acetyl cysteine exert hepatoprotective activity in patients receiving trabectedin and to patients with impaired liver function and renal function.

Conclusion

Trabectedin is a drug that binds to guanine residues in the minor groove of DNA and causes bending of DNA towards major groove which triggers a cascade of events which affects the normal functioning of DNA and its activities such as DNA binding proteins, transcription, DNA repair pathways resulting in the perturbation of the cell cycle and eventual cell death.

In a simple way, Trabectedin is a minor groove binder that is able to induce DNA damage which alters the normal function of the

DNA, its repair and transcription process leading to cessation of cell proliferation and cell differentiation and ultimately leads to cell death.

Trabectedin modulates the tumor microenvironment which can be a reason for its anti-tumor activity.

The hepatotoxicity induced by the trabectedin may lead to impaired liver function and this can be overcome by use of N-acetyl cysteine which is having anti-oxidant properties and exert hepato-protective effect thereby counteracting the important side effect which shows crucial clinical impact in drug induced hepatotoxicity.

References

1. Salvatore Grisanti, Deborah Cosentini, Valeria Tovazzi, Susanna Bianchi, Barbara Lazzari, Francesca Consoli. *et al.*, 2018.
2. Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for soft tissue sarcoma: current status and future perspectives, 2016.
3. Del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S. *et al.* Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. *Med Oncol*, 2013; 30:435
4. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. *Toxicol Sci*. 2002; 65(2):166-1764.
5. Haeussler U, Riedel M, Keller F. Free reactive oxygen species and nephrotoxicity of contrast agents. *Kidney Blood Pressure Res*, 2004; 27(3).
6. Cai Z, Lou Q, Wang F, Li E, Sun J, Fang H. *et al.* N-acetylcysteine protects against liver injury induced by carbon tetrachloride via activation of the Nrf2/HO-1 pathway. *Int J Clin Exp Pathol*. 2015; 8(7):8655-8662.
7. Donald S, Verschoyle RD, Greaves P, Orr S, Jimeno J, Gescher AJ. *et al.* Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. *Cancer Chemother Pharmacol*. 2004; 53:305-312.
8. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C. *et al.* Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. *Eur J Cancer*. 2006; 42:1484-1490.
9. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY. *et al.* Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. *J Clin Oncol*. 2009; 27(25):4188-4196.
10. Food US, Administration D. Prescribing information of Yondelis, 2015.
11. Sales I, Dzierba AL, Smithburger PL, Rowe D, Kane-Gill SL. Use of aacetylcysteine for non-acetaminophen-induced acute liver failure. *Ann Hepatol*. 2013; 12:6-10.
12. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. *Ann Emerg Med*. 1991; 20(10):1058-1063.

13. Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Shah HA. *et al.* Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. *Hepatol Int.* 2009; 3:563-570.
14. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. *N Engl J Med.* 1991; 324:1852-1857. 12
15. Zwingmann C, Bilodeau M. Metabolic insights into the hepatoprotective effect of N-acetylcysteine in mouse liver. *Hepatology.* 2006; 443:454-463.
16. Rehman T, Fought J, Richard Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. *Clin J Am Soc Nephrol.* 2008; 3(6):1610-1614.
17. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with n-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. *Am J Kidney Dis.* 2004.
18. Graziani M, Antonilli L, Togna AR, Grassi MC, Badiani A, Saso L. *et al.* Cardiovascular and hepatic toxicity of cocaine: potential beneficial effects of modulators of oxidative stress, *Oxidative Medicine and Cellular Longevity Article*, 2016.
19. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A. *et al.* Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial *J Oncol*, 2016.
20. La Rowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K. *et al.* Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. *Am J Addict.* 2006; 15(1):105-110.
21. Carter NJ. *Drugs*, 2007.
22. Weiming He, Zhigao Zhang, Dawei Ma. A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinedin. *Angewandte Chemie International Edition*, 2019.
23. Carmen Cuevas and Andrés Francescha, 2008.
24. Maria Cucè, Maria Eugenia Gallo, Cantafio, Maria Anna Siciliano, Caterina Riillo, Daniele Caracciolo, Francesca Scionti. *et al.* *Journal of Hematology & Oncology*, 2019.
25. Jones JD, Sinder BP, Paige D, Koh AJ, Thiele S, Shiozawa Y. *et al.*, 2019.
26. Carminati L. *Carcinogenesis*. Grisanti S, *Support Care Cancer*, 2018.
27. Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. *Drugs.* 2005; 65(2):167-78
28. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. *Semin Oncol* 2007; 34(2 Pt 2):S1-15.
29. American Cancer Society. Cancer facts and figures 2007 [online]. Available from URL: <http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf> [Accessed 2007 Jul 3]
30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf [Accessed 2007 Mar 16]
31. Nielsen OS, Blay JY, Judson IR. Metastatic soft tissue sarcoma: prognosis and treatment options. *Am J Cancer.* 2003; 2(3):211-21.
32. Yovine A, Riofrio M, Blay JY. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. *J Clin Oncol.* 2004; 22(5):890-9.
33. Cormier JN, Pollock RE. Soft tissue sarcomas. *CA Cancer J Clin.* 2004; 54:94-109.
34. Clark MA, Fisher C, Judson I. Soft-tissue sarcomas in adults. *N Engl J Med.* 2005; 353:701-11.
35. Fayette J, Coquard IR, Alberti L. ET-743: a novel agent with activity in soft-tissue sarcomas. *Curr Opin Oncol.* 2006; 18(4):347-53.
36. Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? *Curr Opin Oncol.* 2007; 19:226-340.
37. Aletti GD, Gallenberg MM, Cliby WA. Current management strategies for ovarian cancer. *Mayo Clin Proc.* 2007; 82(6):751-70.
38. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. *Obstet Gynecol.* 2006; 107(6):1399-410.
39. Simmons TL, Andrianasolo E, McPhail K. Marine natural products as anticancer drugs. *Mol Cancer Ther.* 2005; 4(2):333-42.
40. Simoens C, Korst AE, De Pooter CM. *In vitro* interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. *Br J Cancer.* 2003; 89(12):2305-11.
41. Cvetkovic RS, Figgitt DP, Plosker GL. ET-743. *Drugs.* 2002; 62(8):1185-92.
42. Marco E, David-Cordonnier MH, Bailly C. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. *J Med Chem.* 2006; 49(23):6925-9.
43. Friedman D, Hu Z, Kolb EA. Ecteinascidin-743 inhibits activated but not constitutive transcription. *Cancer Res.* 2002; 62(12):3377-81.
44. Herrero AB, Martin-Castellanos C, Marco E. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. *Cancer Res.* 2006; 66(16):8155-62.
45. Minuzzo M, Ceribelli M, Pitarque-Marti M. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. *Mol Pharmacol.* 2005; 68(5):1496-503.
46. Scotlandi K, Perdichizzi S, Manara MC. Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. *Clin Cancer Res.* 2002; 8:3893-903.
47. Izbicka E, Lawrence R, Raymond E. *In vitro* antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. *Ann Oncol.* 1998; 9:981-7.
48. Li WW, Takahashi N, Jhanwar S. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. *Clin Cancer Res.* 2001; 7(9):2908-11.

49. Laverdiere C, Kolb EA, Supko JG. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. *Cancer*. 2003; 98(4):832-40.
50. Takahashi N, Li WW, Banerjee D. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. *Clin Cancer Res*. 2001; 7(10):3251-7.
51. D'Incalci M, Colombo T, Ubezio P. The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. *Eur J Cancer*. 2003; 39:1920-6.
52. Riccardi A, Meco D, Ubezio P. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. *Anticancer Drugs*. 2005; 16(8):811-5.
53. Meco D, Colombo T, Ubezio P. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. *Cancer Chemother Pharmacol*. 2003; 52(2):131-8.
54. Allavena P, Signorelli M, Chieppa M. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. *Cancer Res*. 2005; 65(7):2964-71.
55. Shao L, Kasanov J, Hornicek FJ. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. *Biochem Pharmacol*. 2003; 66(12):2381-95.
56. Manara MC, Perdichizzi S, Serra M. The molecular mechanisms responsible for resistance to ET-743 (Trabectedin; Yondelis) in the Ewing's sarcoma cell line, TC-71. *Int J Oncol*. 2005; 27(6):1605-16.
57. Beumer JH, Buckle T, Ouwehand M. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. *Invest New Drugs*. 2007; 25(1):1-7.
58. Marchini S, Marrazzo E, Bonomi R. Molecular characterisation of two human cancer cell lines selected *in vitro* for their chemotherapeutic drug resistance to ET-743. *Eur J Cancer*. 2005; 41(2):323-33.
59. Donald S, Verschoyle RD, Greaves P. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. *Cancer Res*. 2003; 63(18):5902-8.
60. Puchalski TA, Ryan DP, Garcia-Carbonero R. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. *Cancer Chemother Pharmacol*. 2002; 50(4):309-19.
61. Garcia-Carbonero R, Supko JG, Manola J. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. *J Clin Oncol*. 2004; 22(8):1480-90.
62. Garcia-Carbonero R, Supko JG, Maki RG. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. *J Clin Oncol*. 2005; 23(24):5484-92.
63. Van Kesteren C, Cvitkovic E, Taamma A. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. *Clin Cancer Res*. 2000; 6(12):4725-32.
64. Trabectedin (Yondelis®): summary of product characteristics. Madrid, Spain: Pharma Mar, 2007.
65. National Cancer Institute. Phase II study of ecteinascidin 743 in pediatric patients with recurrent or refractory soft tissue sarcomas or Ewing's sarcoma family of tumors [online]. Available from URL: <http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=329999&version=HealthProfessional&protocolsearchid=3494068> [Accessed 2007 Sep 10]
66. Lau L, Supko JG, Blaney S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. *Clin Cancer Res* 2005; 11(2 Pt 1):672-7.
67. Perez Ruixo JJ, Zannikos P, Hirankarn S. Population pharmacokinetics of trabectedin (ET-743) in subjects with cancer [abstract no. 2030]. *J Clin Oncol*. 2006; 18(Pt 1 Suppl. 24):86.
68. Beumer JH, Rademaker-Lakhai JM, Rosing H. Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2007; 59:825-37.
69. Brandon E, Meijerman I, Klijn JS. *In-vitro* cytotoxicity of ET-743 (trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. *Anticancer Drugs*. 2005; 16:935-43.
70. Brandon E, Sparidans RW, Guijt KJ. *et al.* *In vitro* characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectedin®), a novel marine anti-cancer drug. *Invest New Drugs*. 2006; 24:3-14.
71. Salazar R, Pardo B, Majem M. Phase I clinical and pharmacological trial of trabectedin in 3 hour infusion every 3 weeks in patients with advanced cancer and hepatic function disorder [abstract no. 2080]. *J Clin Oncol*. 2006; 18(Pt 1 Suppl. 24):99.
72. Papadopoulos KP, Chu Q, Patnaik A. Phase I and pharmacokinetics study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors [abstract no. 2029]. *J Clin Oncol*. 2006; 18(Pt 1 Suppl. 24):86.
73. Vidal L, Garcia-Martin M, Tan S. Phase I combination study of trabectedin and carboplatin in advanced solid tumours [abstract no 396P]. *Ann Oncol*. 2004; 15Suppl. 3:106.
74. Morgan JA, Le Cesne A, Chawla S. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I) [abstract no. 10060]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, 2007, 1-5. Chicago (IL)
75. Del Campo J, Roszak A, Ciuleanu T. Phase II open label randomized study of trabectedin given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results [abstract no. 5031]. *J Clin Oncol*. 2006; 18(Pt 1 Suppl. 24):263. Plus poster presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA).